<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34866307</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1582-4934</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of cellular and molecular medicine</Title><ISOAbbreviation>J Cell Mol Med</ISOAbbreviation></Journal><ArticleTitle>Neurofilament markers in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>583</StartPage><EndPage>587</EndPage><MedlinePgn>583-587</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.17100</ELocationID><Abstract><AbstractText>This study aims to determine the serum and cerebrospinal fluid (CSF) levels of neurofilament light chain (NFL) and phosphorylated neurofilament heavy chain (pNFH) in amyotrophic lateral sclerosis (ALS) patients, and to explore their feasibility as valid biomarkers for quantifying disease progression and predicting individual prognosis. 52 patients with ALS and 30 controls with noninflammatory neurological diseases were included. NFL and pNFH levels in serum and CSF were measured by enzyme-linked immunosorbent assay. Our findings showed that serum and CSF levels of NFL and pNFH in ALS patients were significantly increased. These values were negatively correlated with disease duration (except CSF NFL with disease duration) and ALSFRS-r score, and positively correlated with disease progression rate (DPR) and upper motor neuron (UMN) score, but did not correlate with bilateral median and ulnar nerve compound muscle action potential (cMAP) amplitudes (except a weak correlation between CSF NFL and cMAP amplitudes). The optimal cut-off values with high sensitivity and specificity were obtained in ROC curve analysis to discriminate ALS from controls. Kaplan-Meier survival curves illustrated that survival was significantly shorter for patients with higher neurofilament levels at diagnosis. The Cox proportional hazards regressions confirmed that NFL and pNFH were significant predictors of survival. Overall, NFL and pNFH in serum and CSF can be used as reliable biomarkers in ALS.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jiaying</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Encephalopathy, Changzhi Hospital of Traditional Chinese Medicine, Changzhi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Xueli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Junhong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-4434-5599</Identifier><AffiliationInfo><Affiliation>Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cell Mol Med</MedlineTA><NlmUniqueID>101083777</NlmUniqueID><ISSNLinking>1582-1838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">axonal damage</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">neurofilament light chain</Keyword><Keyword MajorTopicYN="N">phosphorylated neurofilament heavy chain</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34866307</ArticleId><ArticleId IdType="pmc">PMC8743649</ArticleId><ArticleId IdType="doi">10.1111/jcmm.17100</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;53:162&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8:e75091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, S&#xfc;ssmuth S, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009;256:615&#x2010;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">19296046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, An J, Shaw CE, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. 2011;117:528&#x2010;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3076545</ArticleId><ArticleId IdType="pubmed">21418221</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeban G. pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:146&#x2010;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">23134506</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaepdryver M, Jeromin A, Gille B, Claeys KG, Poesen K. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;89:367&#x2010;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodovitch A, Boucraut J, Delmont E, et al. Combination of serum and CSF neurofilament&#x2010;light and neuroinflammatory biomarkers to evaluate ALS. Sci Rep. 2021;11:703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803734</ArticleId><ArticleId IdType="pubmed">33436881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto K, Han Y, Song Y, Gao Y. Correlational analysis of ALS progression and serum NfL measured by simoa assay in chinese patients. Front Neurol. 2020;11:579094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7793911</ArticleId><ArticleId IdType="pubmed">33424740</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael K, Teunissen CE, Markus O, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577&#x2010;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012;19:1561&#x2010;1567.</Citation><ArticleIdList><ArticleId IdType="pubmed">22680408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong ZY, Lv GP, Gao LN, et al. Neurofilament subunit L levels in the cerebrospinal fluid and serum of patients with amyotrophic lateral sclerosis. Neurodegener Dis. 2018;18:165&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">29898446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, Martinelli I, Bello L, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74:525&#x2010;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol. 2010;14:1329&#x2010;1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">17903209</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke R, Gray E, Lu CH, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015;2:748&#x2010;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Psychiatry. 2019;90:157&#x2010;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Petzold A, Topping J, Allen K, Malaspina A. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. 2015;86:565&#x2010;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Pfluger C, Singh P, et al. Serial measurements of phosphorylated neurofilament&#x2010;heavy in the serum of subjects with amyotrophic lateral sclerosis. J Neurol Sci. 2015;353:122&#x2010;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">25958264</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu&#x2010;Rumeileh S, Vacchiano V, Zenesini C, et al. Diagnostic&#x2010;prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J Neurol. 2020;267:1699&#x2010;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">32100123</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Ren Y, Zhu W, et al. Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis. J Neurol Sci. 2016;367:269&#x2010;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">27423602</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlaepfer WW, Lee C, Lee MY, Zimmerman UJ. An immunoblot study of neurofilament degradation in situ and during calcium&#x2010;activated proteolysis. J Neurochem. 2010;44:502&#x2010;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">2981285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>